SCHEMBL3565071

SCHEMBL3565071

CN(C)c1ccc(CNCCCN(Cc2ccc3c(c2)OCO3)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.44
PLAUR Q03405 1/20 0.44
GAA P10253 1/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 1/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
APOBEC3A P31941 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPT P10636 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3558567 0.91 SMN1; SMN2 (0.44) GAANOS1NOS2SMN1; SMN2ALDH1A1
SCHEMBL3567756 0.88 MEN1 (0.56) GAASMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL3563466 0.86 ALDH1A1 (0.46) GAASMN1; SMN2ALDH1A1APOBEC3ACTDSP1
SCHEMBL3559611 0.85 SMN1; SMN2 (0.48) GAANOS1NOS2SMN1; SMN2ALDH1A1
SCHEMBL3567257 0.85 ALDH1A1 (0.48) GAASMN1; SMN2ALDH1A1APOBEC3ACTDSP1
SCHEMBL3563107 0.84 HTR5A (0.49) GAANOS1NOS2SMN1; SMN2ALDH1A1
SCHEMBL3566727 0.84 ALDH1A1 (0.45) GAASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3562561 0.84 ALDH1A1 (0.46) GAANOS1NOS2SMN1; SMN2ALDH1A1
SCHEMBL3558583 0.84 NOS2 (0.50) GAANOS1NOS2SMN1; SMN2ALDH1A1
SCHEMBL3610811 0.82 TDP1 (0.48) GAANOS1NOS2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-20100094021-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES KALYPSYS, INC. (US) 2010-04-15 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
US-20070123572-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES KALYPSYS, INC. (US) 2007-05-31 US disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094021-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES DCLK2, TH, DCLK3 MMP9 4704/4885PLAUR 4791/4885GAA 4103/4885
US-20070123572-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES DCLK2, TH, DCLK3 MMP9 4704/4885PLAUR 4791/4885GAA 4103/4885
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 MMP9 2281/4885PLAUR 1947/4885GAA 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.